Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research

MORRISVILLE, N.C. – February 8, 2023 – Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic health records (EHR) to the sponsor’s electronic data capture systems (EDC).

Through the partnership, Syneos Health will use the proXimity platform to automate sponsor data transfers from EHRs to EDCs for clinical trials, helping to accelerate the performance of new therapies for patients. This collaboration support’s the Company’s commitment to listening and learning from sites and adapting to meet their most critical needs.

“At Syneos Health, we are committed to our customers, always. By partnering with Equicare to use proXimity, we are further addressing challenges sites and sponsors face regarding data capture, timelines and quality control,” said Michael Henning, President, Clinical Delivery, Syneos Health. “We’re confident this collaboration will help enhance the clinical trial experience for sites and sponsors by accelerating data entry and management to improve its accuracy and to help speed new therapies to patients.”

Typically, clinical trial subject data is transcribed manually by site coordinators or other staff from the EHR to the EDC, which is time-intensive and error-prone. proXimity automates this process and transfers the selected data from one system to another without the need for manual transcription, dramatically reducing the time needed to transfer data while helping to eliminate transcription errors.

While therapeutically agnostic, the proXimity software was first selected by NEXT Oncology – part of the Syneos Health Catalyst Site Program for phase I studies – as the exclusive tool to automate the transfer of clinical trial data from their EHR to EDC systems to speed the performance of new therapies in clinical trials. The platform now serves as a key tool for clinical trial data management, as well as assists sponsors in gaining access to their data to accelerate cancer research.

In a recently conducted proof of concept exercise where NEXT Oncology utilized proXimity to transfer data from the EHR to the Syneos Health managed EDC database, the data transfer was five times faster than manual entry and the data was transferred with 0% data entry errors, compared to a 3.5% error rate for manual data entry.

“We are using proXimity today for many of our studies and we are realizing the benefits as we are delivering the data to our sponsors more quickly with less errors,” said Dr. Anthony Tolcher, MD, Medical Oncologist and co-founder of NEXT Oncology. “In 2023, NEXT Oncology will utilize proXimity on all studies that utilize Medidata Rave as the EDC. We know this is the future to bring new therapies to cancer patients faster, and we are glad to have Syneos Health’s support with this strategy.”

About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.

Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Syneos Health Investor Relations Contact:

Ronnie Speight

Senior Vice President, Investor Relations

+1 919 745 2745

Investor.Relations@syneoshealth.com

Syneos Health Press/Media Contact:

Gary Gatyas

Executive Director, External Communications

+1 908 763 3428

gary.gatyas@syneoshealth.com

About Equicare Health

Equicare Health is the industry’s leading provider of comprehensive care coordination solutions for oncology. EQUICARE CS™ (ECS) is a multi-facility web-based software tool that facilitates patient engagement including patient reported outcomes, patient navigation, survivorship care and a several other clinical tools. proXimity is a tool set designed to automate data transfer between EMRs and EDCs in support of sponsored clinical trials. For more information, visit please visit www.dataproXimity.com.

Equicare Health Media Contact:

Marnie Sanders VP, proXimity

Equicare Health Inc.

+1.303.506.9050

marnie.sanders@equicarehealth.com

NEXT Oncology Selects proXimity™ to Automate Data Transfer for Clinical Trials

System will accelerate performance evaluation of new drugs in early phase research for cancer patients

(SAN ANTONIO) October 17, 2022 –– NEXT Oncology has selected proXimity™ as the exclusive tool to automate the transfer of clinical trial data from their electronic medical record (EMR) to the electronic data capture (EDC) systems used by sponsor organizations doing clinical trials with NEXT Oncology. This will accelerate the performance of new therapies in clinical trials for patients with cancer.

proXimity™ is an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic medical records (EMR) to the sponsor’s electronic data capture systems (EDC). Typically, this data is transcribed manually by data management employees from the EMR to the EDC, which is time-intensive and error-prone. proXimity™ automates this process and transfers the data from one system to another without the need for manual transcription, dramatically reducing the time needed to transfer data while eliminating transcription errors.

“NEXT Oncology is dedicated to the advancement of new anti-cancer therapies through early phase clinical trials with the goal of providing innovative developments in cancer research and treatment,” said Anthony Tolcher, MD, founder of NEXT and renowned cancer researcher. “This is the future of data transfer, and we are embracing it! We are using proXimity™ today for many of our studies and we are realizing the benefits as we are delivering the data more quickly with less errors to our sponsors. This tool is necessary to speed up clinical trial data management as well as assist our sponsors in gaining access to their data so we can accelerate cancer research. We want to bring new therapies to cancer patients faster.”

In a recently conducted pilot study using proXimity™ to transfer data from the EMR to the EDC, the data transfer using proXimity™ was 5 times faster than manual entry and the data was transferred error free compared to 3.5 % manual entry.

In 2023, NEXT Oncology will utilize proXimity™ on all studies that utilize Medidata Rave as the EDC.

About NEXT Oncology

NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring oncologists and US Oncology, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.

About Equicare Health

Equicare Health is the industry’s leading provider of comprehensive care coordination solutions for oncology. EQUICARE CS™ (ECS) is a multi-facility web-based software tool that facilitates patient engagement including patient reported outcomes, patient navigation, survivorship care and a several other clinical tools. Proximity is a tool set designed to automate data transfer between EMRs and EDCs in support of sponsored clinical trials.

Texas Oncology selects proXimity™ to automate data transfer for clinical trials

VANCOUVER, BC, May 31, 2022 /CNW/ – Texas Oncology has selected proXimity™ as the primary tool to automate the transfer of clinical trial data from the oncology EMR to the electronic data capture (EDC) systems used by biotech, pharmaceutical, and contract research organizations providing clinical trials with Texas Oncology.

proXimity is an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic medical records (EMR) to the sponsor’s electronic data capture systems (EDC). Typically, this data is transcribed manually by data management employees from the EMR to the EDC, which is time-intensive and error-prone. proXimity automates this process and transfers the data from one system to another without the need for manual transcription, dramatically reducing the time needed to transfer data while eliminating transcription errors.

Texas Oncology is a leader in cancer research and clinical trials with more than 1500 patients enrolled annually and, on average, 150+ open national trials. In a recent pilot study conducted using proXimity to transfer data from the EMR to the EDC, the data transfer using proXimity™ was 4.5 times faster than manual entry and the data was transferred error free compared to manual entry.

“We look forward to leveraging proXimity in our ongoing program to combine clinical and operational excellence in the performance of clinical trials. With our large network and mass of data, proXimity holds the potential to not only accelerate data entry and management, but also to significantly improve its accuracy. This is a big win for cancer research and cancer patients in Texas,” said Scott Paulson, M.D. medical oncologist and director of clinical research at Texas Oncology.

About Texas Oncology

Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, Texas Urology Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies. For more information, visit www.TexasOncology.com.

About Equicare Health

Equicare Health is the industry’s leading provider of comprehensive care coordination solutions for oncology. EQUICARE CS™ (ECS) is a multi-facility web-based software tool that facilitates patient engagement including patient reported outcomes, patient navigation, survivorship care and a several other clinical tools. Proximity is a tool set designed to automate data transfer between EMRs and EDCs in support of sponsored clinical trials. For more information, visit www.dataproXimity.com.

Len Grenier, (604) 398-2325, len.grenier@equicarehealth.com

Top